Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus octreotide LAR in first-line treatment of advanced neuroendocrine tumors
2008-007153-13Phase 2Completed
- Sponsor
- ITMO University
- Start
- Apr 2009
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and octreotide in apudoma (NET), neuroendocrine carcinoma (NEC), Bronchopulmonary Carcinoid (BPC) and 1 more, sponsored by ITMO University. Primary endpoint: Response rate. Started Apr 2009; status: completed.
02
Drugs
everolimusoctreotide
03
Conditions
apudoma (NET)neuroendocrine carcinoma (NEC)Bronchopulmonary Carcinoid (BPC)Atypical Bronchial Carcinoid
Beyond the preview
Go deeper on 2008-007153-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007153-13.